Transgene S.A (TNG) | Stock Overview & Key Data
Transgene S.A. | Small-cap | Healthcare
Transgene S.A. | Small-cap | Healthcare
Transgene S.A Performance Comparison
Stock Range
Today's Range
Low: €0.78
High: €0.80
on July 18, 2025
52 Week Range
Low: €0.53
High: €1.21
on May 22, 2025
on August 27, 2024
All-Time High: €13.75 on February 10, 2014
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Market Cap
€110.8M
EPS
-0.29
P/E Ratio (TTM)
N/A
Forward P/E
-1.38
P/B Ratio
6.96
PEG Ratio
-1.38
Div. Yield
N/A
ROE
-220.48%
Beta
0.763
Debt to Equity
68.38
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-639.52%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-51.00%
Return on Equity (TTM)
-220.48%
EBITDA
€-34.4M
Net Income (TTM)
€-34.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.05
Quarterly Revenue Growth (YoY)
-4.50%
Quarterly Earnings Growth (YoY)
150.38%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Transgene S.A TNG | 110.78M Small-cap | -1.27% | -16.13% | 30.00% | 11.43% | 14.71% | -30.36% | -66.67% | -49.02% |
| Medincell S.A MEDCL | 557.56M Mid-cap | -0.25% | -2.79% | 10.57% | -1.36% | -8.78% | 4.03% | 214.96% | 103.05% |
| Abivax SA ABVX | 547.13M Mid-cap | 21.24% | 62.95% | 60.52% | 37.92% | 18.41% | -25.95% | 2.86% | -60.64% |
| Innate Pharma S.A IPH | 145.62M Small-cap | 14.67% | 3.61% | 0.00% | -0.58% | -8.99% | -16.10% | -41.69% | -68.61% |
| Ose OSE | 120.48M Small-cap | 4.93% | 4.52% | -5.84% | -18.78% | -29.35% | -19.03% | -19.27% | -9.83% |
| Sensorion SA ALSEN | 106.99M Small-cap | 6.45% | -13.16% | 94.12% | -50.00% | -48.44% | -50.75% | -19.51% | -70.54% |
Ownership & Short Interest
Insider Ownership
73.29%
Institutional Ownership
0.74%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
25K
Average 90-Day Volume
62K
Transgene S.A Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Transgene S.A would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is TNG's 52-week high and low?
- In the last 52 weeks, Transgene S.A reached a high of €1.21 (on August 27, 2024) and a low of €0.53 (on May 22, 2025).
- What is the market cap and P/E ratio for TNG?
- Curious about Transgene S.A's size and valuation? Its market capitalization stands at 110.78M. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -1.38.
- Does TNG pay dividends? If so, what's the yield?
- As for dividends, Transgene S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Transgene S.A's main competitors or similar companies to consider before investing?
When looking at Transgene S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Medincell S.A
MEDCL557.56M Healthcare Biotechnology 4.03% 214.96% Abivax SA
ABVX547.13M Healthcare Biotechnology -25.95% 2.86% Innate Pharma S.A
IPH145.62M Healthcare Biotechnology -16.10% -41.69% Ose
OSE120.48M Healthcare Biotechnology -19.03% -19.27% Sensorion SA
ALSEN106.99M Healthcare Biotechnology -50.75% -19.51% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Transgene S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Transgene S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -220.48%, the Debt to Equity ratio from the most recent quarter is 68.38, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for TNG?
- Looking at Transgene S.A's growth, its revenue over the trailing twelve months (TTM) was €6M. Compared to the same quarter last year (YoY), quarterly revenue grew by -4.50%, and quarterly earnings saw a YoY growth of 150.38%.
- How much of TNG stock is held by insiders and institutions?
- Wondering who owns Transgene S.A stock? Company insiders (like executives and directors) hold about 73.29% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.74%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.